Dupilumab blocks IL-4/IL-13 signaling, targeting key components of the type 2 (T2) inflammatory cascade: it reduces B-cell class switching toward IgE, suppresses effector T2 signals, and decreases tissue eosinophilia and other T2 markers (3, 21). Here, IL13 is linked to Increased total eosinophil count.